Siemens Healthineers CEO on Antibody Test, Rebalancing Business

The transcript discusses the production and impact of a coronavirus antibody test, including regulatory clearance and production capacity. It covers pricing strategies, market competition, and the company's focus on helping society. The impact of the pandemic on business operations, including the withdrawal of guidance and the effect on non-elective surgeries, is also addressed. Additionally, the transcript explores opportunities in medical production related to coronavirus, such as blood clots and cardiovascular treatment.

How does the company plan to address the impact of the pandemic on its diagnostics business?

What opportunities does the company see in the context of the pandemic?

What is the company's position regarding the development of new products related to coronavirus?